16.9 C
New York
Thursday, May 19, 2022

Pulse Biosciences, Inc. (PLSE) stock is down in the Current market; here is why?

Pulse Biosciences, Inc. (PLSE) stock declined in the current market after announcing its Q4 and fiscal 2021 results. PLSE’s share price is $3.43, losing more than 29% compared to yesterday’s closing price. PLSE stock closed at $4.86 at the end of the last trading session. PLSE’s stock volume was around 168.43K shares in the previous trading session. The current market cap of the company is about $144.01 million.


Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '22.
Small-cap Uranium stocks are booming in 2022! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here. .

Sponsored


PLSE: Q4 and Fiscal 2021 Key Financials

  • Q4 revenue was $844K; last year, the company had zero revenue in the fourth quarter.
  • R&D expense in the fourth quarter was $5.6 million. Previously, in Q4 2020, R&D expense was $4 million.
  • Net loss in Q4 was $15.4 million. Q4 2020 net loss was $13.7 million.
  • Basic and diluted loss per share in Q4 2021 was $0.52; in Q4 2020, it was $0.54.
  • Fiscal 2021 revenue was $1.4 million; the company had zero revenue in fiscal 2020.
  • R&D expense in FY21 was $28.6 million. Previously, in 2020, R&D expense was $26.4 million.
  • Net loss in fiscal 2021 was $63.6 million. The fiscal 2020 net loss was $49.8 million.
  • Basic and diluted loss per share in FY2021 was $2.28; in FY 2020, it was $2.14.

PLSE: Achievements in Fiscal 2021

  • The company recorded revenue for the first time.
  • The company had made different management and strategy changes to focus on different processes related to new system sales.
  • The company appointed two gurus in the industry to help them achieve their goals.
  • The company had started initiatives to cut different general and administration expenses and had some layoffs to decrease expenses.
  • The business accomplished 3 sales of CellFX Systems, two in Q4 2021 and one in Q1 2022.
  • After 11 clinics opted out of the Controlled Launch program in Q1, 20 clinics remain.

Conclusion

The company announced its fiscal 2021 results and recorded increasing losses. Although the company made a major development by achieving its first-ever revenue, the losses made the investors skeptical. PLSE had achieved developments in the business, but losses were too significant, making the investors reluctant about it. The company was a pre-revenue company, and for such companies, investors care about performance rather than revenue.

Related Articles

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Latest Articles